2016-11-08T18:40:46-06:00 2015-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2015-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2016-11-08 1 KARA ADAMS P00023315 9497942300 2015 2017-02-10 21:41:12Z JON KOBASHIGAWA MD 8536 WILSHIRE BOULEVARD 3RD FLOOR BEVERLY HILLS CA 90211 1931246 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 12 7 0 7 0 0 1514534 1784016 30822 146199 12447 1031 0 0 1557803 1931246 0 0 0 0 1474167 1686274 0 0 0 211984 420440 1686151 2106714 -128348 -175468 287831 133728 179546 197995 108285 -64267 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1666886 146199 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2015:SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "A GLOBAL USER'S GUIDE TO MECHANICAL CIRCULATORY SUPPORT", OCTOBER 9-10, 2015 (LOS ANGELES): THIS 2-DAY SYMPOSIUM ON MECHANICAL CIRCULATORY SUPPORT WAS DEVELOPED WITH THE CEDARS-SINAI OFFICE OF CONTINUING MEDICAL EDUCATION AND TOOK PLACE ON OCTOBER 9-10, 2015. IN ADDITION TO UTILIZING THE SIMULATION LABS AT CSMC, THE PROGRAM FEATURED 26 EXPERT GUEST FACULTY FROM ACROSS THE UNITED STATES PLUS 16 INTERNAL FACULTY. THE PROGRAM DREW 200 ATTENDEES INCLUDING PHYSICIANS, ALLIED HEALTH PROFESSIONALS, NURSE PRACTITIONERS, AND TRANSPLANT COORDINATORS AND PROVIDED LEARNERS WITH A COMPREHENSIVE OVERVIEW OF MECHANICAL CIRCULATORY SUPPORT, INCLUDING HANDS-ON EXPERIENCE WITH ICU SCENARIOS AND SKILL LABS.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM", MAY 29TH, 2015 (LONG BEACH, CA): THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, MAY 29TH, 2015. TWENTY-ONE FACULTY SPEAKERS COVERED TOPICS RELATED TO THE PREVENTION AND MANAGEMENT OF HEART FAILURE, HEART TRANSPLANT EVALUATION, POST-TRANSPLANT CARE AND SURGICAL OPTIONS IN HEART FAILURE. THE PROGRAM DREW 201 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS. (MEETING SPONSOR: JON KOBASHIGAWA, MD)* "A CONSENSUS CONFERENCE ON DONOR HEART SELECTION AND MANAGEMENT", MAY 1ST, 2015 (PHILADELPHIA, PA):THIS NATIONAL FORUM WAS PLANNED IN COLLABORATION WITH THE AMERICAN SOCIETY OF TRANSPLANTATION, IN TANDEM WITH THE 2015 AMERICAN TRANSPLANT CONGRESS IN PHILADELPHIA. THIS INVITATION-ONLY MEETING DREW 74 LEADING EXPERTS IN THE FIELD OF HEART TRANSPLANTATION (CARDIOTHORACIC SURGEONS, TRANSPLANT CARDIOLOGISTS, ORGAN PROCUREMENT PROFESSIONALS) TO DISCUSS CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF DONOR HEARTS, INCLUDING OPTIMIZING DONOR HEARTS PRIOR TO TRANSPLANT, NOVEL PRESERVATION METHODS AND THE USE OF MARGINAL ORGANS, WITH A VIEW TOWARD REACHING CONSENSUS ON STRATEGIES TO IMPROVE THE VIABILITY AND EXPAND THE AVAILABILITY OF DONOR HEARTS. (CONFERENCE CHAIR: JON KOBASHIGAWA, MD)* "DISCUSSION FORUM ON UNOS HEART ALLOCATION POLICY CHANGES", MAY 4TH, 2015 (PHILADELPHIA, PA): THIS DISCUSSION FORUM WAS PLANNED AND EXECUTED IN COLLABORATION WITH THE AMERICAN SOCIETY OF TRANSPLANTATION AND TOOK PLACE DURING THE AMERICAN TRANSPLANT CONGRESS AT THE PHILADELPHIA CONVENTION CENTER. THIS MEETING WAS DESIGNED TO PROVIDE A FORUM FOR DISCUSSION AMONG THE CARDIOTHORACIC MEMBERS OF THE AST THAT CAN HELP INFORM AN AST COMMUNITY RESPONSE TO THE INVITATION FOR PUBLIC COMMENT ON NEW PROPOSED CHANGES TO THE UNOS HEART ALLOCATION ALGORITHM. (MEETING CHAIR & MODERATOR: JON KOBASHIGAWA, MD)* "TRANSPLANT NURSING DISCUSSION FORUM", APRIL 17TH, 2015 (NICE, FRANCE): THIS MEETING WAS PLANNED IN COLLABORATION WITH THE NURSING, HEALTH SCIENCE AND ALLIED HEALTH COUNCIL OF THE INTERNATIONAL SOCIETY OF HEART & LUNG TRANSPLANTATION IN TANDEM WITH THE ISHLT ANNUAL MEETING & SCIENTIFIC SESSIONS IN FRANCE. THE FORUM WAS DESIGNED AS A FOLLOW-UP TO THE RECENTLY PUBLISHED ARTICLE FROM THE 2011 CONSENSUS CONFERENCE ON HEART TRANSPLANT NURSING AND PROVIDED A PLATFORM TO IDENTIFY, PRIORITIZE AND PURSUE ISSUES/INITIATIVES CRITICAL TO THE FIELD. A PRE-MEETING SURVEY WAS DISTRIBUTED BROADLY TO ISHLT MEMBERS AND RESULTS WERE USED TO GUIDE DISCUSSIONS AMONGST THE 50 PEOPLE IN ATTENDANCE.(MEETING SPONSOR: JON KOBASHIGAWA, MD) * "A CLINICIAN'S GUIDE TO PULMONARY HYPERTENSION", FEBRUARY 28TH, 2015 (LOS ANGELES, CA): THIS HALF-DAY SYMPOSIUM ON PULMONARY HYPERTENSION TOOK PLACE ON SATURDAY, FEBRUARY 28TH, 2015. EIGHT FACULTY SPEAKERS (7 PHYSICIANS, 1 NURSE PRACTITIONER) COVERED TOPICS RELATED TO THE PREVENTION AND MANAGEMENT OF PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION. THE PROGRAM DREW 67 ATTENDEES CONSISTING OF PHYSICIANS, NURSES, AND ALLIED HEALTH PROFESSIONALS. THE PROGRAM WAS EXTREMELY WELL RECEIVED.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITING PHYSICIANS:SRIKANTH K.V., MDNARAYANA INSTITUTE OF CARDIAC SCIENCESBANGALORE, INDIASARABJEET SINGH, MDBAKERSFIELD HEART HOSPITALBAKERSFIELD, CAMARYJANE FARR, MDCOLUMBIA PRESBYTERIAN, NEW YORK* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO EIGHT STUDENTS FOR THE SUMMER OF 2015. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES:ALLEN RUBIN LIPSON: UNIVERSITY OF CALIFORNIA, LOS ANGELES (UNDERGRAD)ANI AHARONYAN: UNIVERSITY OF CALIFORNIA, LOS ANGELES (UNDERGRAD)EVAN C. NORRIS: GEORGE WASHINGTON UNIVERSITY (MED STUDENT)KENGO Z. SOGHOYAN: UNIVERSITY COLLEGE DUBLIN (MED STUDENT) KRISTIN BUCHER: UNIVERSITY OF CALIFORNIA, SANTA CRUZ (UNDERGRAD)RAYSHMA S. SHAROFF: UNIVERSITY OF CALIFORNIA, LOS ANGELES (UNDERGRAD)TATIANA A. MANAYAN: CALIFORNIA STATE UNIVERSITY, SACRAMENTO (POST GRAD)CLINICAL RESEARCH:THIS SECTION WILL BE FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.ADVANCED HEART DISEASE REGISTRY; JON KOBASHIGAWA, MD; ENROLLING; CSMCBIOMARKERS OF PRIMARY GRAFT DYSFUNCTION AFTER CARDIAC TRANSPLANTATION; JON KOBASHIGAWA, MD; STUDY START-UP; COLUMBIA UNIVERSITYCELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; JON KOBASHIGAWA, MD; ENROLLING; CSMC/CAREDX, INC.DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY; JON KOBASHIGAWA, MD; APPROVED/NOT YET ENROLLING; UNIVERSITY OF ALBERTAEXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY: JON KOBASHIGAWA, MD; ENROLLING; CSMCHDL LEVELS AND CARDIAC ALLOGRAFT VASCULOPATHY (CAV); JON KOBASHIGAWA, MD; ENROLLING; CSMCHOME ECG MONITORING TO DETECT ALLOGRAFT REJECTION FOLLOWING HEART TRANSPLANTATION; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; UCSF/NIHOUTCOMES ALLOMAP REGISTRY (OAR) STUDY; JON KOBASHIGAWA, MD; ENROLLING; CAREDX, INC.RISK STRATIFICATION PRIOR TO TANDEM ORTHOTOPIC HEART AND STEM CELL TRANSPLANT IN PATIENTS WITH SYSTEMIC AMYLOIDOSIS; JON KOBASHIGAWA, MD; ENROLLING; CSMCA MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL BPS-314D-MR ADDED-ON TO TREPROSTINIL, INHALED (TYVASO) IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; LUNG BIOTECHNOLOGY, INC.A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS 1666886 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 X 12 7 1 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 590 ENCINO CA 91436 JON KOBASHIGAWA MD CHIEF MEDICAL DIRECTOR 2.00 0.00 X X 0 0 0 KEENAN BEHRLE CHAIRPERSON 2.00 0.00 X X 0 0 0 JAMES HAMILTON SECRETARY 2.00 0.00 X X 0 0 0 THOMAS D GORDON CFO 1.00 65.00 X X 0 1262766 233241 MICHELE HAMILTON MD DIRECTOR 2.00 0.00 X 0 0 0 RICHARD B JACOBS DIRECTOR 1.00 61.00 X 0 1128846 315441 JOSEPH O LAMPE DIRECTOR 2.00 0.00 X 0 0 0 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 3033529 203082 LAURENCE MARTON MD DIRECTOR 2.00 0.00 X 0 0 0 ARTHUR J OCHOA DIRECTOR 1.00 65.00 X 0 899862 58422 WILLIAM OUCHI PHD DIRECTOR 2.00 0.00 X 0 0 0 EDWARD PRUNCHUNAS DIRECTOR 1.00 65.00 X 0 1598972 343438 ERIC N MARTON PRESIDENT 30.00 30.00 X 0 427457 32397 CHRISTINE SUMBI VICE-PRESIDENT 40.00 0.00 X 0 163644 21801 0 8515076 1207822 0 0 1 0 0 1784016 1784016 EDUCATIONAL PROGRAMS 611430 137902 137902 CULTURAL PROGRAMS 611710 8297 8297 146199 1031 1031 1931246 146199 0 1031 411149 411149 1084864 1084864 55821 55821 76717 76717 57723 57723 759 759 23204 16774 6430 21776 19598 2178 75568 75568 11357 11357 207740 197353 10387 5498 5498 MEALS AND ENTERTAINMENT 52879 47591 5288 DUES & SUBSCRIPTIONS 8960 8960 BAD DEBT EXPENSE 4159 4159 MOVING/STORAGE 1920 1920 6620 2983 3637 2106714 1666886 439828 0 24343 47646 462 486 107678 101031 12145 6647 250881 78949 287831 133728 172546 180995 7000 17000 179546 197995 X 108285 -64267 108285 -64267 287831 133728 -175468 2916 0 X 0 0 0 X 1280861 1445229 1357431 1514534 1784016 7382071 1280861 1445229 1357431 1514534 1784016 7382071 7382071 18834 12225 8138 5075 1031 45303 7427374 346594 0.99390 0.91370 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 70594 63947 6647 37084 37084 0 6647 0 1 0 0 0 0 0 0 0 THOMAS D GORDON CFO 0 551650 0 288345 0 422771 0 205564 0 27677 0 1496007 0 150000 RICHARD B JACOBS DIRECTOR 0 597485 0 334748 0 196613 0 299978 0 15463 0 1444287 0 0 EDUARDO MARBAN MD DIRECTOR 0 1305135 0 359065 0 1369329 0 168550 0 34532 0 3236611 0 655589 ARTHUR J OCHOA DIRECTOR 0 528652 0 277911 0 93299 0 24488 0 33934 0 958284 0 0 EDWARD PRUNCHUNAS DIRECTOR 0 730868 0 507908 0 360196 0 317613 0 25825 0 1942410 0 0 ERIC N MARTON PRESIDENT 0 357300 0 45650 0 24507 0 10600 0 21797 0 459854 0 0 CHRISTINE SUMBI VICE-PRESIDENT 0 144394 0 19250 0 0 0 11072 0 10729 0 185445 0 0 PART I, LINE 3 THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. IN ADDITION, TWO INDIVIDUALS HAVE A RETENTION INCENTIVE WHICH HAD A CLIFF VESTING DATE IN 2015. THE FOLLOWING OFFICERS, DIRECTORS, AND KEY EMPLOYEES RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2015. THOMAS D. GORDON 393,862 RICHARD B. JACOBS 153,227 EDUARDO MARBAN, MD 1,144,868 ERIC N. MARTON 22,696 ARTHUR J. OCHOA 88,034 EDWARD PRUNCHUNAS 298,699 FORM 990, PART III, LINE 4A (CONTINUED) A PHASE 3, PLACEBO CONTROLLED DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (INO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH); ANTOINE HAGE, MD; STUDY START-UP; BELLEROPHON PULSE TECHNOLOGIES LLC A PHASE III, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL WORSENING STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING BACKGROUND ORAL MONOTHERAPY; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; STUDY START-UP; REATA PHARMACEUTICALS, INC. AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS); BABAK AZARBAL, MD; STUDY START-UP; DALCOR PHARMA UK LTD A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; DAVID CHANG, MD; ENROLLING; TEVA PHARMACEUTICALS A PROSPECTIVE, RANDOMIZED, CONTROLLED, UNBLINDED, MULTI-CENTER CLINICAL TRIAL TO EVALUATE THE HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM FOR DESTINATION THERAPY OF ADVANCED HEART FAILURE; JAIME MORIGUCHI, MD; ENROLLING; HEARTWARE, INC. PULMONARY HYPERTENSION POST-LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION; JAIME MORIGUCHI, MD; STUDY START-UP; ACTELION PHARMACEUTICALS A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; PFIZER A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) MEDIATED FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY (FAC); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; ALNYLAM PHARMACEUTICALS A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE 20MG OR 80MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; STUDY START-UP; PFIZER THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL; JIGNESH PATEL, MD, PHD; ENROLLING; ALEXION PHARMACEUTICALS OBSERVATIONAL REVIEW OF CLINICAL OUTCOMES IN HEART FAILURE PATIENTS UNDERGOING BARIATRIC SURGERY; MICHELE HAMILTON, MD; ENROLLING; CSMC REGISTRY EVALUATION OF VITAL INFORMATION FOR VADS IN AMBULATORY LIFE; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UNIVERSITY OF MICHIGAN THE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UAB/NIH FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/15 AND 6/30/16 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/15. FORM 990, PART VI, SECTION A, LINE 2 LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, PRESIDENT HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11 THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 HEALTHCARE CA 501(C)(3) LINE 3 N/A 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 200 N ROBERTSON BOULEVARD 101 BEVERLY HILLS CA 90211 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 11A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 2001 SANTA MONICA 360W SANTA MONICA CA 90404 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A ISS ASC HOLDINGS LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A DEL REY SURGERY INVESTORS LLC 11150 SANTA MONICA B STE 700 LOS ANGELES CA 90025 364756208 INVESTMENT IN AMBULATORY SURGERY CENTER DE N/A DEL REY SURGERY CENTER LLC 4640 ADMIRALTY WAY STE 1020 MARINA DEL REY CA 90292 462305372 OPERATOR OF AMBULATORY SURGERY CENTER CA N/A GRTR VALLEY MGMT SVCS ORG INC 6500 WILSHIRE BLVD 9TH FLR LOS ANGELES CA 90048 954439758 MANAGEMENT FUNCTIONS CA N/A C 1 OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLOOR LOS ANGELES CA 90048 954522779 INFORMATION SYSTEMS CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 593811890 MEDICAL OFFICE BUILDING CA N/A C 1 OTOHARMONICS CORPORATION 411 SW 6TH AVE PORTLAND OR 97204 461119421 HEALTHCARE PRODUCT DEVELOPMENT DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0